Review of Comprehensive Computerized Insulin Dose Adjustment Algorithms: a Technology to Aid Primary Care Clinicians
Main Article Content
Abstract
Background - Primary care clinicians, who take care of 90% of people with diabetes, are challenged managing patients taking insulin. Insulin-requiring patients remain poorly controlled, especially those on intensive insulin regimens. The senior author developed and taught detailed treatment protocols to 50 non-physician primary care clinicians so that they could independently manage patients with diabetes. The principles of adjusting insulin doses were computerized and subsequently cleared by the Federal Drug Administration and registered by the Confirmite Europeene.
Aims – to evaluate the effectiveness and safety of these comprehensive computerized insulin dose adjustment algorithms (called Insulin Insights).
Methods – Insulin Insights interacts with over 60 glucose meters as well as continuous glucose monitors, handles all approved insulins and analyzes 11 different insulin regimens. Insulin Insight’s algorithms that are located in electronic health records or office computers generate reports within 1-2 minutes after glucose readings are downloaded. Algorithms located on a secure, approved icloud source for remote monitoring send reports at agreed upon time intervals to primary care clinicians. The generated report includes a scatterplot of glucose readings, the values organized into before and after each meal and before bedtime, an analysis of the glucose patterns that are presented in bar graphs and recommendations for dose adjustments (if necessary) that can be accepted or modified. The new doses serve as the basis for the next report.
Results - There were 104 patients in formal studies (2 pre- post and 2 randomized control trials) evaluating the response to Insulin Insights in which changes in scheduled measured HbA1c levels were the primary outcome. Baseline HbA1c levels fell 1.8% from 9.8% to 8.0% over 4.7 months. Another 161 patients were followed in real world situations. Since HbA1c tests were not at scheduled intervals, estimated HbA1c levels based on average glucoses were analyzed in all 265 patients and also showed a significant decrease. There was no increase in hypoglycemia attesting to the safety of Insulin Insights.
Conclusion – Insulin Insights, utilized by primary care clinicians, enabled them to significantly improve glycemic control. They also educate the primary care clinicians and save them time.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Calvert MJ, McManis RJ, Freemantle N. Management of type 2 diabetes with multiple oral hyperglycaemic agents or insulin in primary care retrospective cohort study. Br J Gen Pract 2007;57: 455-460.
3. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010;6: e418-e424.
4. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 2011;94: 352-363.
5. Mata-Cases M, Franch-Nadal J, Real J, Gratacos M, Lopez-Simarro F, Khunti K, et al. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment. Diabetes Obes Metab 2018;20:103-112.
6. Kostev K, Rathmann W. Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010). Prim Care Diabetes 2013;7:229-233.
7. Jeavons D, Hungin APS, Cornford CS. Patients with poorly controlled diabetes in primary care: healthcare clinicians’ beliefs and attitudes. Postgrad Med J 2006;82:347-350.
8. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006;32:1342-1349.
9. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY Survey. Diabetes Educ 2011;37:111-123.
10. Patrick AR, Fischer MA, Choudry NK, Shrank WH, Seeger JD, Liu J, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J. Gen Intern Med 2013;29:320-327.
11. Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab 2016; 18:401-409.
12. Ascher-Svanum H, Lage M, Perez-Nieves M, Reaney MD, Lorraine J, Rodriquez A. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther 2014;5: 225-242.
13. Bonafede M, Chandran A, DiMano S, Saltiel-Berzin R, Saliu D. Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study. BMJ Open Diabetes Research and Care 2016:4e000189. doi:10.1136/bmjdrc-2015-00189.
14. Andreozzi F, Candido R, Corrao S, Forengo R, Giancaterini A, Ponzani P, et al. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetol Metab Syndr 2020;12:52.
15. Venkatraman S, Echouffo-Tcheugui J, Selvin E, Fang M. Trends and disparities in glycemic control and severe hyperglycemia among US adults with diabetes using insulin, 1988-2020 JAMA Netw Open, 2022. 5(12): p. e2247656.
16. Davidson MB. Insulin analogues: is there a compelling case to use them? No! Diabetes Care 2014;37:1771-1774.
17. Bowering K, Case C, Harvey J, Reeves M, Sampson M. Strzinek R, et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 Trial. Diabetes Care 2017;40:951-957.
18. Russell-Jones D, Bode BW, De Block C, Franek C, Heller SR, Monthieu C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017:40:943-950.
19. Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, et al. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin degludec, in children and adolescents with type 1 diabetes: the onset 7 Trial. Diabetes Care 2019;42:1255-1262.
20. Bowering K, Harvey J, Kolaczynski JW, Snyder JW, Bode BW. A randomized trial evaluating the efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with or without metformin, in adults with type 2 diabetes (ONSET 9). Diabetic Med 2019;36:771-775.
21. Lane WS, Favaro E, Rathor N, Jang HC, Kjaersgaard MIS, Oviedo A, et al. A randomized trial evaluating the efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both in combination with insulin inulin degludec with or without metformin, in adults with type 2 diabetes (ONSET 9). Diabetes Care 2020;43:1710-1716.
22. Lee MH, Paldus B, Vogrin S, Morrison D, Zaharieva DP, Lu J, et al. Fast-acting insulin-aspart versus insulin aspart using a second-generation hybrid closed-loop system in adults with type 1 diabetes: a randomized, open-label, crossover trial. Diabetes Care 2021;44:2371-2378.
23. Blevins T, Zhang Q, Frias J, Jinnouchi, H, Chang A, for the PRONTO-T2D Investigators. Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care 2020;43:2991-2998.
24. Bode BW, McGill JB, Lorber D, Gross JL, Chang P-C, Bregman DB, for the Affinity 1 Study Group. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care 2015;38:2266-2273.
25. Hirsch IB, Beck RW, Marak MC, Kudva Y, Atkurk HK, Bhargava A, et al. A randomized trial comparing inhaled insulin plus basal insulin versus usual care in adults with type 1 diabetes. Diabetes Care 2025; 48:353-360.
26. Davidson MB, Blanco-Castellanos M, Duran P. integrating nurse-directed diabetes management into a primary care setting. Am J Manag Care 2010; 16:652-656.
27. Scarlett LD, Jenne KW, Duran P, Woodcock E. Goodman KM, Davidson MB. Glycemic effect of using patient-defined meal sizes instead of CHO counting to determine bolus doses of insulin. Diabetes 2025 Jun, 74 (Suppl 1).
28. Davidson MB, Davidson SJ. Effect of remote glucose monitoring utilizing computerized insulin dose adjustment algorithms: a pilot project. Diabetes Ther 2019;10:523-533.
29. Davidson MB, Davidson SJ: Effective use of computerized insulin dose adjustment algorithms on continuous glucose monitoring results by a clinical pharmacist – proof of concept. J Diabetes 2021;13:439-441.
30. Pulicharam J, Davidson SJ, Bubb C, Evans S, Davidson MB, 2022. Effect of incorporating computerized insulin dose adjustment algorithms into a remote patient monitoring program on HbA1c levels in patients with type 2 diabetes. Medical Research Archives, [online] 10(12).
doi.org/10.18103/mra.v10i12.3396.
31. Amante DJ, Harlan DM, Lemon SC, McManus DD, Olaitan OO, Pagoto SL, et al. Evaluation of a diabetes remote monitoring program facilitated by connected glucose meters for patients with poorly controlled type 2 diabetes: randomized crossover trial. JMIR Diabetes 2021;6:e25574.
32. Menon A, Tornvall I, Bennetts D, Nugapitiya S, Varnfield M, Davidson M, Russell A. Rethinking the model of care of outpatient diabetes service. ATTD-ASIA 2024: Diabetes Conference, 18-20 November (kenes.com).
33. Stone RA, Rao RH, Sevick MA, Cheng C, Hough LT, Macpherson DS, et al. Active care management supported by home telemonitoring in veterans with type 2 diabetes: the DiaTel randomized controlled trial. Diabetes Care 2010;33:478–484.
34. Tildesley HD, Mazanderani AB, Ross SA. Effect of internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin. Diabetes Care 2010;33:1738–1740.
35. Bashan E, Herman WH, Hodish I. Are glucose readings sufficient to adjust insulin dosage? Diabetes
Technol Ther 2011;13:85–92.
36. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
37. Robinson S, Newson Rs, Liao B, Kenndey-Martin T, Battelino T. Missed and mistimed insulin doses in people with diabetes: a systematic literature review. Diabetes Technol Therap 2021;23:844-856.
38. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-689.
39. Divilly P, Martinez-Edith G, Zaremba N, Soholm U, Mahmoudi A, Cigler M, et al. Relationship between sensor-detected hypoglycemia and patient-reported hypoglycemia in people with type 1 and insulin-treated type 2 diabetes: the Hypo-METRICS Study. Diabetes Care 2024;47:1769-1777.
40. Gavin JR, Abaniel RM, Virdi NS. Therapeutic inertia and delays in insulin intensification in type 2 diabetes: a literature review. Diabetes Spectr 2023; 36:379-384.